Ovid Therapeutics Inc.

OVID

Ovid Therapeutics Inc.

OVID

Insider Sentiment (TTM):

Last Purchase:2025-01-27Last Sale:2026-02-23Shares Purchased (TTM):0Shares Sold (TTM):20,197

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:104,923,057Shares Outstanding:N/AInstitutional Ownership Pct.:N/A

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	11	94	13	21	28	21	26	15	30	31	27	57
Available For Sale Securities Debt Securities Curr…	106	61	56	5	10	22	27	48	47	59	79	30
Prepaid Expense And Other Assets Current	6	5	5	3	4	3	3	3	4	3	4	5
Assets Current	124	160	74	29	42	46	56	66	81	93	110	92
Long Term Investments	-	-	-	21	21	21	21	21	21	22	18	16
Available For Sale Securities Debt Securities Nonc…	53	10	21	-	-	-	0	-	-	-	-	-
Equity Securities Without Readily Determinable Fai…	43	42	42	-	-	-	21	-	-	-	-	-
Restricted Cash	2	2	2	2	2	2	2	2	2	2	2	2
Operating Lease Right Of Use Asset	11	11	12	12	12	13	13	13	13	14	14	14
Property Plant And Equipment Net	0	0	0	0	0	0	0	1	1	1	1	1
Other Assets Noncurrent	-	-	0	0	0	0	0	0	0	0	0	0
Assets	232	226	151	64	77	82	92	103	118	132	144	125
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	4	9	2	2	4	2	3	3	5	4	4	1
Accrued Liabilities Current	4	5	5	3	3	6	6	8	8	4	7	6
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Contract With Customer Liability	-	-	-	1	1	-	-	-	-	-	-	-
Liabilities Current	10	16	8	7	9	9	11	12	14	9	11	9
Liabilities Noncurrent
Operating Lease Liability Noncurrent	11	12	12	12	13	13	13	14	14	14	15	15
Liabilities	22	27	20	19	22	22	24	26	29	53	56	24
Stockholders Equity
Preferred Stock Value	-	-	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	564	537	452	376	375	374	372	371	370	368	366	364
Accumulated Other Comprehensive Income Loss Net Of…	-1	-0	-0	-0	-0	-0	-0	0	-0	-0	0	-0
Retained Earnings Accumulated Deficit	-354	-339	-322	-331	-319	-315	-304	-295	-281	-290	-278	-263
Stockholders Equity	210	198	131	45	56	59	68	76	89	78	88	101
Liabilities And Stockholders Equity	232	226	151	64	77	82	92	103	118	132	144	125
Preferred Stock Par Or Stated Value Per Share	-	-	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	315	315	125	125	125	125	125	125	125	125	125	125
Common Stock Shares Issued	185	167	130	71	71	71	71	71	71	71	71	71
Shares Outstanding	185	167	130	71	71	71	71	71	71	71	71	71
Preferred Stock Shares Authorized	-	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	-	-	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-16.38%	-6.27%	-22.65%	-	-	-	-	-	-	-	-	-
2025	11.54%	18.18%	74.83%	43.36%	114.45%	62.00%	26.52%	33.33%	18.18%	19.57%	21.74%	4.35%
2024	-8.36%	-76.90%	-70.28%	16.17%	30.98%	29.84%	-7.26%	-22.26%	-46.53%	-42.45%	-33.88%	-44.49%
2023	-	-	-	-	-	-	-6.72%	-3.92%	-12.04%	-0.97%	0.65%	-2.60%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	12.39	10.17	8.97	4.24	4.72	4.93	5.32	5.66	5.73	10.47	9.55	10.59
Quick Ratio	11.75	9.88	8.40	3.77	4.30	4.62	5.04	5.39	5.45	10.14	9.22	10.05
Working Capital	113.64M	144.40M	66.08M	22.03M	33.17M	36.61M	45.42M	54.20M	66.77M	84.27M	98.13M	83.05M
Leverage & Debt
Debt to Equity	0.11	0.14	0.16	0.43	0.39	0.38	0.35	0.35	0.33	0.68	0.64	0.23
Debt Ratio	0.10	0.12	0.13	0.30	0.28	0.27	0.26	0.26	0.25	0.41	0.39	0.19
Efficiency & Turnover
Asset Turnover TTM	0.01	0.05	0.06	0.08	0.07	0.01	0.00	0.01	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-	-	-14,871.05	-29,064.80	-30,543.20	-19,979.20	-21,146.40	-26,000.80	-23,798.40	-40,541.60	-41,871.20	-0.69
Free Cash Flow Per Share TTM	-0.30	-0.25	-32,736.12	-30,364.80	-32,076.00	-39,688.00	-44,828.00	-46,343.20	-42,380.80	-40,320.00	-36,656.80	-0.61
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-3,686.67%	-670.25%	-585.20%	-618.32%	-625.08%	-10,404.74%	-10,933.75%	-10,972.78%	-11,998.42%	-13,039.24%	-15,122.70%	-17,978.23%
Net Profit Margin TTM	-2,178.90%	-339.33%	-240.13%	-549.64%	-574.03%	-4,557.30%	-4,670.14%	-5,142.56%	-5,237.32%	-10,691.35%	-13,351.79%	-16,377.00%
Growth Metrics
Net Revenue Growth (1Y)	-76.20%	1,199.64%	1,181.27%	945.89%	1,070.95%	15.61%	44.39%	113.31%	186.32%	284.17%	-73.91%	-79.66%
Net Income Growth (1Y)	-9.66%	-3.23%	-34.12%	11.78%	28.34%	-50.72%	-49.50%	-33.02%	-39.58%	-1.44%	-3.38%	-32.29%
EPS Growth (1Y)	-100.00%	-100.00%	-29.68%	11.78%	28.34%	-50.72%	-49.50%	3,784,056.36%	3,409,156.63%	5,557,998.34%	5,443,548.77%	-32.47%
Valuation Metrics
P/E TTM	-14.41	-15.37	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-0.00	-5.59
P/B TTM	2.37	1.87	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.68
P/S TTM	313.96	52.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01	915.27
Market Cap	496.99M	371.33M	1.91K	1.62K	412.50	390.00	1.17K	1.47K	961.25	3.81K	4.03K	271.18M
Enterprise Value	483.73M	275.34M	-15.08M	-22.54M	-30.35M	-23.07M	-28.23M	-16.95M	-31.62M	-32.70M	-28.97M	211.81M
Calculated Values
Free Cash Flow TTM	-54.77M	-41.95M	-38.33M	-37.96M	-40.10M	-49.61M	-56.04M	-57.93M	-52.98M	-50.40M	-45.82M	-43.19M
Net Debt	-13.26M	-96.00M	-15.08M	-22.54M	-30.35M	-23.07M	-28.23M	-16.95M	-31.63M	-32.70M	-28.97M	-59.37M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-23Sale

Owner: Alexander, Margaret A.

Title: President and CEO

Shares: 11,656

Price/Share: $1.45

Value: $16,901.20

Shares Owned: 61,750

Relationship: Director,Officer

Ownership: Direct

2026-02-23Sale

Owner: Rona, Jeffrey A

Title: CBFO

Shares: 8,541

Price/Share: $1.45

Value: $12,384.45

Shares Owned: 88,188

Relationship: Officer

Ownership: Direct

2025-02-26Sale

Owner: Alexander, Margaret A.

Title: President and COO

Shares: 5,279

Price/Share: $0.56

Value: $2,956.24

Shares Owned: 73,406

Relationship: Officer

Ownership: Direct

2025-02-26Sale

Owner: Rona, Jeffrey A

Title: CBFO

Shares: 3,902

Price/Share: $0.56

Value: $2,185.12

Shares Owned: 67,973

Relationship: Officer

Ownership: Direct

2025-01-27Purchase

Owner: Alexander, Margaret A.

Title: President and COO

Shares: 6,810

Price/Share: $0.73

Value: $4,971.30

Shares Owned: 34,935

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-23	Alexander, Margaret A.	Director,Officer	President and CEO	Direct	Sale	11,656	1.45	$16,901.20	61,750	4
2026-02-23	Rona, Jeffrey A	Officer	CBFO	Direct	Sale	8,541	1.45	$12,384.45	88,188	4
2025-02-26	Alexander, Margaret A.	Officer	President and COO	Direct	Sale	5,279	0.56	$2,956.24	73,406	4
2025-02-26	Rona, Jeffrey A	Officer	CBFO	Direct	Sale	3,902	0.56	$2,185.12	67,973	4
2025-01-27	Alexander, Margaret A.	Officer	President and COO	Direct	Purchase	6,810	0.73	$4,971.30	34,935	4
2024-03-18	Levin, Jeremy M	Director,Officer	CEO	Direct	Purchase	18,248	2.76	$50,364.48	3,616,715	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

Inst. Shares: 104,923,057

Shares Outstanding: -

2025-12-31

Inst. Shares: 60,521,244

Shares Outstanding: 1,171

2025-09-30

Inst. Shares: 33,255,361

Shares Outstanding: 1,250

2025-06-30

Inst. Shares: 32,299,867

Shares Outstanding: 1,250

2025-03-31

Inst. Shares: 43,022,627

Shares Outstanding: 1,250

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	104,923,057	0	-
2025-12-31	60,521,244	1,171	-
2025-09-30	33,255,361	1,250	-
2025-06-30	32,299,867	1,250	-
2025-03-31	43,022,627	1,250	-
2024-12-31	44,742,291	1,250	-
2024-09-30	35,770,067	1,250	-
2024-06-30	35,505,127	1,250	-
2024-03-31	39,319,365	1,250	-
2023-12-31	38,410,906	1,250	-
2023-09-30	36,670,370	70,618,609	51.93%
2023-06-30	35,238,026	70,534,181	49.96%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Ovid Therapeutics Inc. (OVID) — SEC Financial Statements & Analysis

Ovid Therapeutics Inc. (OVID) is a pharmaceutical preparations company, incorporated in DE. Ovid Therapeutics Inc. trades on Nasdaq as: OVID. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Ovid Therapeutics Inc. reported a -76.20% year-over-year revenue growth, a Debt-to-Equity ratio of 0.11x, a Price-to-Sales (P/S) ratio of 313.96x (TTM), a Price-to-Book (P/B) ratio of 2.37x (TTM), at a market cap of $496.99M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -76.20%
Debt To Equity: 0.11x
P/S TTM: 313.96x
P/B TTM: 2.37x
Market Cap: $496.99M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Ovid Therapeutics Inc. in?

Ovid Therapeutics Inc. (OVID) operates in the Pharmaceutical Preparations industry.

What is OVID's market cap?

Ovid Therapeutics Inc. (OVID) has a market capitalization of $496.99M as of 2026-06-30.

What exchange does OVID trade on?

Ovid Therapeutics Inc. (OVID) trades on the Nasdaq.

Where is Ovid Therapeutics Inc. incorporated?

Ovid Therapeutics Inc. is incorporated in DE.